Related Experiment Videos
[Bisphosphonates-related jaw osteonecrosis].
S Abi Najm1, S Lysitsa, J P Carrel
1Division de stomatologie, chirurgie orale et radiologie dentomaxillo-faciale, Faculté de Médecine, Genève. abns77@hotmail.com
Presse Medicale (Paris, France : 1983)
|December 13, 2005
Summary
Bisphosphonates treat bone disorders but can cause jaw osteonecrosis. This study suggests bisphosphonate dosage may be key to preventing this side effect, especially when no other risk factors are present.
Area of Science:
- Oral and Maxillofacial Surgery
- Pharmacology
- Oncology
Background:
- Bisphosphonates are crucial for managing Paget's disease, osteoporosis, and bone tumors.
- Increasing reports link bisphosphonate use to osteonecrosis of the jaw (ONJ).
- Potential predisposing factors for ONJ include surgery, chemotherapy, and radiotherapy.
Purpose of the Study:
- To present 9 cases of maxillary osteonecrosis observed over 12 months.
- To investigate the potential role of bisphosphonates as a primary cause of ONJ.
Main Methods:
- Retrospective case series analysis.
- Clinical observation and treatment of 9 patients with maxillary osteonecrosis.
Main Results:
- Nine cases of maxillary osteonecrosis were identified and treated.
- Three of the nine cases lacked identifiable predisposing factors.
Conclusions:
- Bisphosphonates may directly cause ONJ by inhibiting bone remodeling and leading to excessive mineralization.
- Excessive bisphosphonate dosage could be a primary etiological factor.
- Optimizing bisphosphonate dosage may be crucial for preventing ONJ.